First data from the ORACLE prospective clinical utility study highlights reduction of invasive procedures on patients with benign nodules BOULDER, Colo. --(BUSINESS WIRE)--Oct. 13, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced that

Data highlight the importance of utilizing genomic and proteomic testing for treatment guidance BOULDER, Colo. --(BUSINESS WIRE)--Sep. 16, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts

BOULDER, Colo. --(BUSINESS WIRE)--Sep. 2, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present in a fireside chat the Morgan Stanley Virtual 19th

BOULDER, Colo. --(BUSINESS WIRE)--Aug. 25, 2021-- Biodesix, Inc. (Nasdaq: BDSX). Today Biodesix announced that the Accreditation Committee of the College of American Pathologists (CAP) and British Standards Institute (BSI) on behalf of International Organization for Standardization (ISO) recently

Second Quarter 2021 Revenue of $11.9 Million Increased 180% and Lung Diagnostic Revenue of $4.8 Million Increased 109% over Second Quarter 2020 Announcing Acceleration of the Launch of the 72-hour liquid NGS Test to Early First Quarter 2022 Conference Call and Webcast Today at 4:30 p.m.

BOULDER, Colo. --(BUSINESS WIRE)--Aug. 2, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton , Chief Executive Officer of Biodesix , will present at the Canaccord Genuity 41st Annual Growth Conference

BOULDER, Colo. --(BUSINESS WIRE)--Jul. 27, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the second quarter ended June 30, 2021 after the close of trading on Tuesday,

Biodesix and Seer to discuss combined efforts to utilize Seer Proteograph™ Product Suite to drive novel proteomic insights for translational research BOULDER, Colo. --(BUSINESS WIRE)--Jun. 17, 2021-- Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced

Detection of circulating neutralizing antibodies produced in response to COVID-19 vaccination and infection may benefit immunocompromised individuals. BOULDER, Colo. --(BUSINESS WIRE)--Jun. 15, 2021-- Biodesix, Inc.   (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus

Biodesix intends to make its databank and linked data accessible to research and biopharma partners BOULDER, Colo. & SAN FRANCISCO --(BUSINESS WIRE)--Jun. 4, 2021-- Biodesix, Inc.  (Nasdaq: BDSX),   a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant,